ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose without erythropoiesis-stimulating agents for iron deficiency anemia in patients with gastric/colorectal cancer receiving chemotherapy

A Multicenter Phase II Trial of Encorafenib, Binimetinib and Cetuximab for Early Relapsed Stage II/III BRAFV600E-mutated Colorectal Cancer: TRESBIEN trial (OGSG 2101)

A Multicenter Phase II Trial of Encorafenib, Binimetinib and Cetuximab for Early Relapsed Stage II/III BRAF⁠V600E-mutated Colorectal Cancer TRESBIEN trial (OGSG 2101)

Surgical resection Improves Survival Even in Chemotherapy Responders with Stage IV Gastric Cancer: Secondary Analysis of the OGSG2301

Exploratory Subgroup Analysis of Pathological Response in Long-term Outcomes of Perioperative CapeOx: OGSG1701

ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for iron deficiency anemia in patients with gastric/colorectal cancer receiving chemotherapy

Perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701)

Characteristics of conversion surgery cases for gastric cancer-Multicenter retrospective cohort study (OGSG2301)-

高度リンパ節転移を伴う進行胃癌に対する周術期Capecitabine＋Oxaliplatin (CapeOx)療法第II相試験(OGSG1701) ：3年間の追跡結果

Re-evaluating the neutropenia–survival paradigm in irinotecan-based therapy for advanced gastric cancer: post-hoc analysis of the RINDBeRG trial